More than 350 billion in revenue is not enough! Sinopharm group plans to launch the seventh listed company

With the intensive disclosure of the annual reports of listed companies, the 2017 performance of six listed companies under Sinopharm group, including Sinopharm holding, Sinopharm, Sinopharm and Sinopharm congruence, also surfaced Sinopharm group's revenue exceeded 300 billion yuan in 2016 and exceeded 350 billion yuan in 2017 Recently, according to media reports, Sinopharm and its medical device business are preparing to merge, which will take Sinopharm as the main body and seek to be listed separately to impact a share The report pointed out that after the Spring Festival this year, Sinopharm and its subordinate equipment businesses began to seek merger, and the two sides are in the process of organizational structure adjustment The specific plan has not been clarified yet At present, Sinopharm group has 6 listed companies If Sinopharm devices are successfully listed, it will become the seventh listed company, and will focus on the group's medical device business However, how did the giant Guoyao group make it? What is the performance of its six listed companies in 2017? Performance of H-share listed companies of Sinopharm group in 2017 (unit: RMB 100 million); performance of A-share listed companies of Sinopharm group in 2017 (unit: RMB 100 million) none = "shifumousedownstyle ('shifu_bus_002 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: RGB (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> in 2017, the income of Sinopharm holdings reached 277.717 billion yuan, a year-on-year increase of 7.48%; the profit margin was 7.868 billion yuan, a year-on-year increase of 14.17%; the parent company's holders should account for 5.283 billion yuan, a year-on-year increase of 13.68% Among them, the pharmaceutical distribution revenue was 264.352 billion yuan, up 7.26% year-on-year, accounting for more than 90% of the total revenue, mainly due to the sound development of pharmaceutical distribution business and further expansion of distribution network; the retail business revenue was 12.392 billion yuan, up 21.03% year-on-year, mainly due to the acquisition and expansion and the growth of stock drugstores' own business; the other business revenue was 3.962 billion yuan List of income of Sinopharm Holdings (unit: 1000 yuan) Consolidation of leading position of pharmaceutical distribution: as of December 31, 2017, the distribution network under Sinopharm Holdings has covered 31 provinces, municipalities and autonomous regions in China; direct customers include 15032 hospitals (only referring to classified hospitals, including the largest and highest level three-level hospitals 2301), small-scale end customers (including primary medical institutions, etc.) 128326, and retail pharmacies 87246 In addition, we continued to strengthen the construction of the national integrated logistics platform, and successfully completed the sinking planning of the distribution network The national pharmaceutical distribution logistics network includes 4 hub logistics centers, 42 provincial logistics centers, 236 Prefecture and city level logistics outlets, 26 retail logistics outlets, and 308 total network points   Leading in retail scale industry: Sinopharm has set up direct or franchised retail chain drugstores in major cities across the country As of December 31, 2017, the stores of its subsidiary Sinopharm Guoda pharmacy Co., Ltd cover 19 provinces, municipalities and autonomous regions across the country It has 3834 retail drugstores, including 2801 Direct stores and 1033 franchised stores, with a year-on-year rapid growth in sales and scale Keep leading in the industry In the future, on the one hand, Sinopharm will continue to promote the sinking of the distribution network, optimize the network layout, further play to the scale and network advantages, and constantly consolidate the leading position of the industry We will actively grasp the window of policy opportunities, rapidly increase the share of direct sales of hospitals, further promote regional integration, establish a regional enterprise cluster with unified management and control, diverse services, flexible coordination and efficient operation, and lay the foundation for national integration On the other hand, we will actively learn from international advanced technology and experience, and form a national layout, in-depth development, reasonable structure, wholesale and retail integration, multi profit point, anti risk ability, internationalization and overall leading drug retail terminal network by continuing to expand retail business   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> summary of Chinese traditional medicine performance (unit: 1000 yuan) Chinese traditional medicine covers Chinese traditional medicine seed collection, Chinese herbal pieces, formula granules, Chinese patent medicine, Chinese traditional medicine big health and other industries, which is the core platform of Chinese medicine industry of Sinopharm group The company has more than 700 kinds of single traditional Chinese medicine formula granules, more than 60 classic compound granules and 979 patent products, of which 282 are included in the 2017 national medical insurance drug catalog, including 26 exclusive products Xianlinggubao capsule / tablet, Yupingfeng granule, Biyankang tablet, Jingshu granule, Runzaozhiyang capsule, Fengshigutong capsule, Zaoren Anshen capsule and Qili capsule are the exclusive products in the national basic drug catalog China's traditional Chinese medicine focuses on the development of herbal pieces and formula granules, steadily promotes the business of proprietary Chinese medicine, and actively explores the extension of the business form of the health sector of traditional Chinese medicine In addition, carry out extended M & A to promote the layout of the whole industrial chain In 2017, the business volume of traditional Chinese medicine reached 8.338 billion yuan, a year-on-year increase of 27.6%; the owners of the company accounted for 1.170 billion yuan of profit, a year-on-year increase of 21.0% Main financial indicators of TCM formula granule business (unit: 1000 yuan) Through two major mergers and acquisitions of Guizhou Tongjitang Pharmaceutical Co., Ltd and Jiangyin Tianjiang Pharmaceutical Co., Ltd and its subsidiary companies (Tianjiang pharmaceutical for short), China's traditional Chinese medicine has rapidly expanded from a single proprietary medicine business to the whole industry chain of traditional Chinese medicine covering herbal pieces, herbal formula particles, proprietary medicine and health services In 2017, the turnover of Tianjiang pharmaceutical industry grew rapidly, reaching 5.5 billion yuan, a year-on-year growth of 26.2%, accounting for 66.0% of the total turnover The growth of performance is mainly due to the following five aspects: first, the continuous growth of market demand; second, the public hospitals retain the markup of the sales of Chinese herbal pieces (including formula granules); third, on the basis of the sales network covering 30 provinces (municipalities directly under the central government), strengthen the market penetration and hospital coverage; fourth, increase the academic promotion, and the average sales volume of the second and third level TCM hospitals has significantly improved; Fifth, the market of intelligent dispensing machine has increased significantly   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> main accounting data of Sinopharm (unit: 10000 yuan) Note: in October 2016, Sinopharm sold the overall operating assets of the company's Pingshan pharmaceutical R & D base by subscribing 15.56% of the newly issued shares of the related party modern pharmaceutical, as well as 51% equity of each of its three pharmaceutical industry subsidiaries, including Zhijun pharmaceutical, Zhijun medical trade and Pingshan pharmaceutical Accordingly, the comparative statements of the consolidated income statement and cash flow statement contain the income statement and cash flow statement data of three industrial companies from January to October 2016 In 2017, the consistent operating revenue of Sinopharm was 41.264 billion yuan, an increase of 0.04% year on year; the net profit was 1.058 billion yuan, a decrease of 10.85% year on year For the decline of net profit, Sinopharm unanimously said that it was mainly due to the significant asset restructuring in October 2016, and the statement included the data of the three industrial companies' profit statements from January to October 2016 Excluding this factor, operating revenue increased by 3.01% year on year, and net profit increased by 9.08% year on year Sinopharm's main business in 2017 (unit: 10000 yuan) Note: industries and products listed in the above table account for more than 10% of revenue or operating profit Sinopharm's consistent pharmaceutical distribution business is mainly based on Guangdong and Guangxi According to the annual report, the network construction of Guangdong and Guangxi was completed in 2013, and the business extended to county-level areas In 2014, the integration of three-level companies was accelerated In 2015, the whole network operation was realized In 2016, the network was further expanded, including 1660 hospitals above the first level, 3348 primary medical customers and 1447 retail terminal customers In the pharmaceutical retail business, Guoda pharmacy, affiliated to Guoyao, is one of the few enterprises in China that has a nationwide direct drug retail network Its retail chain network covers 19 provinces, autonomous regions and municipalities directly under the central government, and nearly 70 large and medium-sized cities By the end of 2017, Guoda pharmacy had 3834 stores, forming a pharmacy network covering the coastal city groups of East China, North China and South China, and gradually spread into the northwest, Central Plains and inland city groups   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> main accounting data of Sinopharm (unit: 10000 yuan) in 2017, the operating revenue of Sinopharm was 36.285 billion yuan, an increase of 4.84% year on year; net profit was 1.141 billion yuan, an increase of 15.28% year on year Sinopharm's performance mainly comes from commodity sales, product sales and warehousing logistics In terms of commodity sales, i.e the headquarters and subsidiaries of Sinopharm Group Pharmaceutical Co., Ltd., Sinopharm Beijing, Sinopharm Huahong, Sinopharm Tianxing, Sinopharm Kangchen, Sinopharm prospect, Sinopharm Jiankun and Sinopharm Airport (a part of them), belong to the pharmaceutical business, which are the main revenue and profit source of the company; in terms of product sales, i.e the holding subsidiary of Sinopharm group Guorui Pharmaceutical Co., Ltd., the main For the pharmaceutical industry Main business of Sinopharm in 2017 (unit: 10000 yuan) after the completion of the integration of commercial resources in Beijing, Sinopharm realized the coverage of secondary and tertiary hospitals in Beijing, and more than 3000 primary medical institutions, with sales of secondary and tertiary hospitals ranking first in the region In addition, narcotic drugs and class I psychotropic drugs have been the most core competitive business of Sinopharm for many years Among the three national wholesale enterprises of narcotic drugs and class I psychotropic drugs, the market share has been maintained at more than 80% The retail direct sales business has covered the top 500 chain stores and many single drugstores in China, with direct channels covering more than 30000 stores and channel extension covering more than 80000 stores   According to the annual report of Sinopharm, in January 2017, the restructuring project was unconditionally approved by the reorganization committee of China Securities Regulatory Commission, and the major asset restructuring entered the implementation stage; in May, four target companies successfully completed the industrial and commercial change procedures, raising 1.03 billion yuan of supporting funds; in June, the new share issuance and additional share issuance registration were completed, and the registered capital of the company was changed to 767 million yuan, completing the merger of restructuring Report work.